Point72 Asset Management L.P. reduced its position in Boston Scientific Corporation (NYSE:BSX) by 88.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 125,500 shares of the medical equipment provider’s stock after selling 922,000 shares during the quarter. Point72 Asset Management L.P.’s holdings in Boston Scientific were worth $3,661,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Swiss National Bank boosted its position in shares of Boston Scientific by 2.9% in the second quarter. Swiss National Bank now owns 5,584,930 shares of the medical equipment provider’s stock worth $154,814,000 after purchasing an additional 156,800 shares during the period. Wells Fargo & Company MN boosted its position in shares of Boston Scientific by 10.5% in the second quarter. Wells Fargo & Company MN now owns 9,157,768 shares of the medical equipment provider’s stock worth $253,854,000 after purchasing an additional 867,983 shares during the period. Sit Investment Associates Inc. boosted its position in shares of Boston Scientific by 37.8% in the third quarter. Sit Investment Associates Inc. now owns 141,710 shares of the medical equipment provider’s stock worth $4,134,000 after purchasing an additional 38,855 shares during the period. Greenwood Capital Associates LLC boosted its position in shares of Boston Scientific by 71.7% in the third quarter. Greenwood Capital Associates LLC now owns 91,579 shares of the medical equipment provider’s stock worth $2,671,000 after purchasing an additional 38,249 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. boosted its position in shares of Boston Scientific by 35,016.2% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 3,042,464 shares of the medical equipment provider’s stock worth $84,337,000 after purchasing an additional 3,033,800 shares during the period. Institutional investors and hedge funds own 90.36% of the company’s stock.

Shares of Boston Scientific Corporation (BSX) opened at $25.49 on Wednesday. The stock has a market cap of $35,401.00, a price-to-earnings ratio of 21.13, a P/E/G ratio of 1.99 and a beta of 0.96. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.50 and a current ratio of 0.72. Boston Scientific Corporation has a 12 month low of $21.32 and a 12 month high of $29.93.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.31. The company had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.21 billion. Boston Scientific had a net margin of 9.55% and a return on equity of 23.60%. Boston Scientific’s revenue was up 5.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.27 earnings per share. equities analysts forecast that Boston Scientific Corporation will post 1.25 EPS for the current year.

In other Boston Scientific news, insider Valley Gold Master Fund L. Sun purchased 408,006 shares of the firm’s stock in a transaction that occurred on Tuesday, November 28th. The shares were bought at an average price of $0.45 per share, with a total value of $183,602.70. Also, EVP Timothy A. Pratt sold 10,000 shares of the company’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $26.04, for a total transaction of $260,400.00. Following the sale, the executive vice president now directly owns 154,681 shares in the company, valued at approximately $4,027,893.24. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 424,698 shares of company stock worth $12,273,553. 0.74% of the stock is owned by insiders.

BSX has been the topic of several research analyst reports. BidaskClub downgraded shares of Boston Scientific from a “hold” rating to a “sell” rating in a report on Saturday, August 26th. Royal Bank of Canada reissued a “buy” rating and issued a $31.00 target price on shares of Boston Scientific in a report on Friday, September 1st. Jefferies Group reissued a “hold” rating on shares of Boston Scientific in a report on Thursday, September 7th. Stifel Nicolaus reissued a “buy” rating and issued a $32.00 target price on shares of Boston Scientific in a report on Monday, September 25th. Finally, SunTrust Banks reissued a “buy” rating and issued a $34.00 target price on shares of Boston Scientific in a report on Monday, October 2nd. One research analyst has rated the stock with a sell rating, four have issued a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $31.03.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://www.watchlistnews.com/boston-scientific-corporation-bsx-holdings-decreased-by-point72-asset-management-l-p/1774400.html.

Boston Scientific Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.